Shandong Buchang Pharmaceuticals Co (SHSE:603858) EBIT: ¥659 Mil (TTM As of Mar. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Shandong Buchang Pharmaceuticals Co Ltd SHSE:603858

70 GF Score

Price ¥15.66

GF Value ¥15.94

Valuation Fairly Valued

6 Warning Signs

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

What is Shandong Buchang Pharmaceuticals Co EBIT?

Shandong Buchang Pharmaceuticals Co SHSE:603858 -0.89% 70 EBIT is ¥659 Mil as of Mar. 2026. GuruFocus rates SHSE:603858 with a GF Score™ of 70/100 and a GF Value™ of ¥15.94 (Fairly Valued). The stock has 6 warning signs investors should review.

Shandong Buchang Pharmaceuticals Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥411 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥659 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shandong Buchang Pharmaceuticals Co's annualized ROC % for the quarter that ended in Mar. 2026 was 10.53%. Shandong Buchang Pharmaceuticals Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 32.86%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shandong Buchang Pharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.54%.

Try GuruFocus Premium free for 7 days

Unlock GF Score, GF Value, 30-Y financials, and pro screeners.

Get Started →

Shandong Buchang Pharmaceuticals Co (SHSE:603858) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shandong Buchang Pharmaceuticals Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	1760.828 * ( 1 - 20.77% )	/	( (13191.425	+	13309.595)	/ 2 )
=	1395.1040244	/	13250.51
=	10.53 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	19244.71	-	5330.75	-	( 1257.514	-	max(0, 7170.975	-	7893.51	+	1257.514	))
=	13191.425

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	19640.475	-	4824.635	-	( 1868.845	-	max(0, 6994.919	-	8501.164	+	1868.845	))
=	13309.595

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Shandong Buchang Pharmaceuticals Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	1645.216	/	( ( (4795.809 + max(-111.26, 0))	+	(4712.313 + max(504.802, 0)) )	/	2 )
=	1645.216	/	( ( 4795.809	+	5217.115 )	/	2 )
=	1645.216	/	5006.462
=	32.86 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(674.277	+	4500.301	+	430.166)	-	(5330.75	+	0	+	385.254)
=	-111.26

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(617.444	+	4581.479	+	464.653)	-	(4824.635	+	0	+	334.139)
=	504.802

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shandong Buchang Pharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	659.091	/	18607.582
	=	3.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Buchang Pharmaceuticals Co EBIT Related Terms

Shandong Buchang Pharmaceuticals Co EBIT Historical Data

* Premium members only.

The historical data trend for Shandong Buchang Pharmaceuticals Co's EBIT can be seen below:

Shandong Buchang Pharmaceuticals Co EBIT Chart

Shandong Buchang Pharmaceuticals Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

1,753.86

-1,124.29

504.49

-235.70

652.66

Shandong Buchang Pharmaceuticals Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															404.87	404.59	299.71	-456.51	411.30

SHSE:603858 vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Buchang Pharmaceuticals Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shandong Buchang Pharmaceuticals Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shandong Buchang Pharmaceuticals Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shandong Buchang Pharmaceuticals Co's EV-to-EBIT falls into.

Save Embed

70GF Score

Shandong Buchang Pharmaceuticals Co Ltd SHSE:603858

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

Shandong Buchang Pharmaceuticals Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥659 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of ¥659 Mil mean?

Shandong Buchang Pharmaceuticals Co (SHSE:603858) has a EBIT of ¥659 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shandong Buchang Pharmaceuticals Co.

Is Shandong Buchang Pharmaceuticals Co's EBIT too high?

Shandong Buchang Pharmaceuticals Co's current EBIT is ¥659 Mil. Overall, Shandong Buchang Pharmaceuticals Co has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Shandong Buchang Pharmaceuticals Co's EBIT compare to ZTS?

Shandong Buchang Pharmaceuticals Co's EBIT of ¥659 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Drug Manufacturers company?

A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shandong Buchang Pharmaceuticals Co. Shandong Buchang Pharmaceuticals Co's current EBIT is ¥659 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Shandong Buchang Pharmaceuticals Co stock overvalued right now?

Based on GuruFocus' analysis, Shandong Buchang Pharmaceuticals Co (SHSE:603858) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.94, compared to a current price of ¥15.66 — trading 1.8% below its estimated fair value. The current EBIT is ¥659 Mil. Shandong Buchang Pharmaceuticals Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Shandong Buchang Pharmaceuticals Co (SHSE:603858), the current EBIT is ¥659 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shandong Buchang Pharmaceuticals Co (SHSE:603858) Overvalued in 2026?

Based on GuruFocus' analysis, Shandong Buchang Pharmaceuticals Co stock appears to be undervalued. The current stock price of ¥15.66 is trading 1.8% below its estimated GF Value™ of ¥15.94. GuruFocus considers Shandong Buchang Pharmaceuticals Co to be Fairly Valued.

Key valuation signals for SHSE:603858:

EBIT: ¥659 Mil
GF Value™: ¥15.94 vs. price of ¥15.66 (1.8% below fair value)
GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the SHSE:603858 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →